Memantine approved to treat moderate to severe Alzheimer’s disease

Current Neurology and Neuroscience Reports

Volumn 4, Issue 5, 2004, Pages 349-350

  Marder, Karen ^a  

^a NONE

Author keywords

Cholinesterase Inhibitor; Memantine; Memantine Treatment; Milacemide; Vascular Dementia

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT;

AGITATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING INVENTORY; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE PLUS CAREGIVER INPUT; DEMENTIA ASSESSMENT; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HIV ASSOCIATED DEMENTIA; HUMAN; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTIINFARCT DEMENTIA; NOTE; SEVERE IMPAIRMENT BATTERY; SIDE EFFECT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ALZHEIMER DISEASE; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MEMANTINE; PLACEBOS;

EID: 7944231205     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-004-0080-y     Document Type: Note

References (4)

1. Reisberg B, Doody R, Stoffler A, et al., for the Memantine Study gnGroup: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003, 348:1333–1341.
2. Tariot P, Farlow M, Grossberg, et al., for the Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004, 291:317–324.
3. Doraiswamy PM: The role of the N-methyl-D-aspartate receptor in Alzheimer’s disease: therapeutic potential. Curr Neurol Neurosci Rep 2003, 3:373–378.
4. Lipton SA: Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx: J Am Soc Exp NeuroTherapeutics 2004, 101–110.